What is Satigene?
Satigene (Satigene) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
Satigene is used to treat cancers of the colon and rectum. It is usually given with other cancer medicines in a combination chemotherapy.
Satigene may also be used for purposes not listed in this medication guide.
Satigene indications
As a single-agent or combination treatment of patients with: Metastatic carcinoma of the colon or rectum that has recurred or progressed following 5-fluorouracil (5-FU)-based therapy; previously untreated metastatic carcinoma of the colon or rectum; non-small-cell lung cancer (NSCLC); small-cell lung cancer; cervical and ovarian cancer; inoperable or recurrent gastric cancer; esophageal cancer.
Satigene in combination with cetuximab is indicated for the treatment of patients with EGFR-expressing metastatic colorectal cancer after failure of Satigene-including cytotoxic therapy.
Satigene in combination with 5-FU, folinic acid (FA) and bevacizumab is indicated for 1st-line treatment of patients with metastatic carcinoma of the colon or rectum.
As a single-agent treatment of patients with glioma.
How should I use Satigene?
Use Satigene as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Satigene is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Satigene at home, a health care provider will teach you how to use it. Be sure you understand how to use Satigene. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.
- Do not use Satigene if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.
- Drink plenty of water and other clear liquids while using Satigene.
- If you spill Satigene on your skin, wash it off right away with soap and water.
- Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.
- If you miss a dose of Satigene, contact your doctor right away.
Ask your health care provider any questions you may have about how to use Satigene.
Uses of Satigene in details
This medication is used to treat cancer of the colon and rectum.
OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.
This drug may also be used to treat other types of cancer (such as lung, bone cancer).
How to use Satigene intravenous
This medication is given by injection into a vein by a health care professional. The dosage is based on your medical condition, body size, and response to treatment.
If this medication comes into contact with your skin, wash the skin right away and completely with soap and water. If this medication gets into your eyes, mouth, or nose, flush completely with plenty of water. Consult your doctor for more details.
Satigene description
DBL Satigene Injection Concentrate is an antineoplastic agent of the topoisomerase I inhibitor class.
Satigene is a semisynthetic derivative of camptothecin, an alkaloid extract from plants such as Camptotheca acuminata. It is a pale yellow to yellow crystalline powder, with the empirical formula C33H38N4O6·HCl·3H2O and a molecular weight of 677.19.
Its chemical name is (4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidinopiperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)dione hydrochloride trihydrate.
DBL Satigene Injection Concentrate is supplied as a sterile, aqueous solution of pH 3.5. It is intended for dilution with 5% Glucose Injection or 0.9% Sodium Chloride Injection prior to infusion. The 2 mL and 5 mL injections contain 40 mg and 100 mg of Satigene trihydrate, respectively. In addition to Satigene trihydrate, the ingredients are sorbitol and lactic acid. Sodium hydroxide and hydrochloric acid are used for pH adjustment.
Satigene dosage
Adults: Monotherapy (for previously treated patients): Recommended Dose: 350 mg/m2 administered as an IV infusion over a 30- to 90- min period every 3 weeks.
Combination Therapy (for previously untreated patients): Safety and efficacy of Satigene in combination with 5-fluorouracil (5-FU) and folinic acid (FA) has been assessed in the following schedule: Satigene Plus 5-FU/FA in a 2-Weekly Schedule: Recommended Dose: 180 mg/m2 administered once every 2 weeks as an IV infusion over a 30 to 90- minutes period, followed by infusion with folinic acid and 5-fluorouracil.
Dose Adjustments: Satigene should be administered after appropriate recovery of all adverse events to grade 0 to 1 NCI-CTC grading (National Cancer Institute Common Toxicity Criteria) and when treatment-related diarrhoea is fully resolved.
At the start of a subsequent infusion of therapy, the dose of Satigene and 5-FU when applicable, should be decreased according to the worst grade of adverse events observed in the prior infusion. Treatment should be delayed by 1-2 weeks to allow recovery from treatment-related adverse events.
With the following adverse events, a dose reduction of 15-20% should be applied for Satigene and/or 5-FU when applicable: Haematological toxicity [neutropenia grade 4, febrile neutropenia (neutropenia grade 3-4 and fever grade 2-4), thrombocytopenia and leucopenia (grade 4)] and nonhaematological toxicity (grade 3-4).
Treatment Duration: Treatment with Satigene should be continued until there is objective progression of the disease or unacceptable toxicity.
Special Populations: Patients with Impaired Hepatic Function: In patients with bilirubin up to 1.5 times the upper limit of the normal range (ULN), the recommended dosage of Satigene is 350 mg/m2. In patients with bilirubin ranging from 1.5 to 3 times ULN the recommended dosage is 200 mg/m2. PATIENTS WITH BILIRUBIN BEYOND 3 TIMES THE ULN SHOULD NOT BE TREATED WITH Satigene.
Patients with Impaired Renal Function: Satigene is not recommended for use in patients with impaired renal function as studies in this population have not been conducted.
Elderly: No specific pharmacokinetic studies have been performed in the elderly. However, the dose should be chosen carefully in this population due to their greater frequency of decreased biological functions. This population therefore requires more intensive surveillance.
Administration: Preparation for IV Infusion: As with any other injectable drugs, the Satigene solution must be prepared aseptically.
Aseptically withdraw the required amount of Satigene solution from the vial with a calibrated syringe and inject into a 250-mL infusion bag or bottle containing either 0.9% sodium chloride or a 5% dextrose solution. The infusion should then be thoroughly mixed by manual rotation.
Satigene infusion solution should be infused into a peripheral or central vein.
Satigene should not be delivered as an IV bolus or an IV infusion <30 min or >90 minutes.
Satigene interactions
See also:
What other drugs will affect Satigene?
5-Fluorouracil (5-FU) And Leucovorin (LV)
In a phase 1 clinical study involving Satigene, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of Satigene was not substantially altered when the drugs were co-administered. Although the Cmax and AUC0-24 of SN-38, the active metabolite, were reduced (by 14% and 8%, respectively) when Satigene was followed by 5-FU and LV administration compared with when Satigene was given alone, this sequence of administration was used in the combination trials and is recommended. Formal in vivo or in vitro drug interaction studies to evaluate the influence of Satigene on the disposition of 5-FU and LV have not been conducted.
Strong CYP3A4 Inducers
Exposure to Satigene or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. John's wort. The appropriate starting dose for patients taking these or other strong inducers such as rifampin and rifabutin has not been defined. Consider substituting non-enzyme inducing therapies at least 2 weeks prior to initiation of Satigene therapy. Do not administer strong CYP3A4 inducers with Satigene unless there are no therapeutic alternatives.
Strong CYP3A4 Or UGT1A1 Inhibitors
Satigene and its active metabolite, SN-38, are metabolized via the human cytochrome P450 3A4 isoenzyme (CYP3A4) and uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1), respectively,. Patients receiving concomitant ketoconazole, a CYP3A4 and UGT1A1 inhibitor, have increased exposure to Satigene and its active metabolite SN-38. Coadministration of Satigene with other inhibitors of CYP3A4 (e.g., clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) or UGT1A1 (e.g., atazanavir, gemfibrozil, indinavir) may increase systemic exposure to Satigene or SN-38. Discontinue strong CYP3A4 inhibitors at least 1 week prior to starting Satigene therapy. Do not administer strong CYP3A4 or UGT1A1 inhibitors with Satigene unless there are no therapeutic alternatives.
Satigene side effects
See also:
What are the possible side effects of Satigene?
Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Common adverse reactions ( ≥ 30%) observed in combination therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, mucositis, neutropenia, leucopenia (including lymphocytopenia), anemia, thrombocytopenia, asthenia, pain, fever, infection, abnormal bilirubin, and alopecia.
Common adverse reactions ( ≥ 30%) observed in single agent therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, neutropenia, leukopenia (including lymphocytopenia), anemia, asthenia, fever, body weight decreasing, and alopecia.
Serious opportunistic infections have not been observed, and no complications have specifically been attributed to lymphocytopenia.
First-Line Combination Therapy
A total of 955 patients with metastatic colorectal cancer received the recommended regimens of Satigene in combination with 5-FU/LV, 5-FU/LV alone, or Satigene alone. In the two phase 3 studies, 370 patients received Satigene in combination with 5-FU/LV, 362 patients received 5-FU/LV alone, and 223 patients received Satigene alone.
In Study 1, 49 (7.3%) patients died within 30 days of last study treatment: 21 (9.3%) received Satigene in combination with 5-FU/LV, 15 (6.8%) received 5-FU/LV alone, and 13 (5.8%) received Satigene alone. Deaths potentially related to treatment occurred in 2 (0.9%) patients who received Satigene in combination with 5-FU/LV (2 neutropenic fever/sepsis), 3 (1.4%) patients who received 5-FU/LV alone (1 neutropenic fever/sepsis, 1 CNS bleeding during thrombocytopenia, 1 unknown) and 2 (0.9%) patients who received Satigene alone (2 neutropenic fever). Deaths from any cause within 60 days of first study treatment were reported for 15 (6.7%) patients who received Satigene in combination with 5-FU/LV, 16 (7.3%) patients who received 5-FU/LV alone, and 15 (6.7%) patients who received Satigene alone. Discontinuations due to adverse events were reported for 17 (7.6%) patients who received Satigene in combination with 5FU/LV, 14 (6.4%) patients who received 5-FU/LV alone, and 26 (11.7%) patients who received Satigene alone.
In Study 2, 10 (3.5%) patients died within 30 days of last study treatment: 6 (4.1%) received Satigene in combination with 5-FU/LV and 4 (2.8%) received 5-FU/LV alone. There was one potentially treatment-related death, which occurred in a patient who received Satigene in combination with 5-FU/LV (0.7%, neutropenic sepsis). Deaths from any cause within 60 days of first study treatment were reported for 3 (2.1%) patients who received Satigene in combination with 5-FU/LV and 2 (1.4%) patients who received 5-FU/LV alone. Discontinuations due to adverse events were reported for 9 (6.2%) patients who received Satigene in combination with 5FU/LV and 1 (0.7%) patient who received 5-FU/LV alone.
The most clinically significant adverse events for patients receiving Satigene-based therapy were diarrhea, nausea, vomiting, neutropenia, and alopecia. The most clinically significant adverse events for patients receiving 5-FU/LV therapy were diarrhea, neutropenia, neutropenic fever, and mucositis. In Study 1, grade 4 neutropenia, neutropenic fever (defined as grade 2 fever and grade 4 neutropenia), and mucositis were observed less often with weekly Satigene/5-FU/LV than with monthly administration of 5-FU/LV.
Tables 5 and 6 list the clinically relevant adverse events reported in Studies 1 and 2, respectively.
Table 5: Study 1: Percent (%) of Patients Experiencing Clinically Relevant Adverse Events in Combination Therapies Other includes events such as accidental injury, hepatomegaly, syncope, vertigo, and weight loss
The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as Satigene than when these drugs were given on separate days (1.3%, 1/80 patients). The 8.5% incidence of akathisia, however, is within the range reported for use of prochlorperazine when given as a premedication for other chemotherapies.
Postmarketing Experience
The following adverse reactions have been identified during post approval use of Satigene. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Myocardial ischemic events have been observed following Satigene therapy. Thromboembolic events have been observed in patients receiving Satigene.
Symptomatic pancreatitis, asymptomatic pancreatic enzyme elevation have been reported. Increases in serum levels of transaminases (i.e., AST and ALT) in the absence of progressive liver metastasis have been observed.
Hyponatremia, mostly with diarrhea and vomiting, has been reported.
Transient dysarthria has been reported in patients treated with Satigene; in some cases, the event was attributed to the cholinergic syndrome observed during or shortly after infusion of Satigene.
Interaction between Satigene and neuromuscular blocking agents cannot be ruled out. Satigene has anticholinesterase activity, which may prolong the neuromuscular blocking effects of suxamethonium and the neuromuscular blockade of non-depolarizing drugs may be antagonized.
Satigene contraindications
See also:
What is the most important information I should know about Satigene?
DBL Satigene Injection Concentrate is contraindicated in patients with a known hypersensitivity to Satigene or to any excipients of DBL Satigene. DBL Satigene Injection Concentrate antigenicity has not been observed in clinical trials, but Satigene antigenicity occurred in tests for passive cutaneous anaphylaxis in guinea pigs and rabbits and in tests for active systemic anaphylaxis in guinea pigs. In these tests, both animal species produced antibodies against Satigene and some deaths occurred in guinea pigs sensitised to Satigene.
DBL Satigene Injection Concentrate is contraindicated in women who intend to become pregnant.
DBL Satigene Injection Concentrate is contraindicated in pregnancy and lactation.
Chronic inflammatory bowel disease and/or bowel obstruction; bilirubin 3 times the upper limit of the normal range; severe bone marrow failure; WHO performance status >2; concomitant use with St. John's Wort.
Active ingredient matches for Satigene:
Irinotecan in Argentina.
Irinotecan hydrochloride in Argentina.
List of Satigene substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Pipetecan 100 (Paraguay) | |
| Proto-Itecan (Brazil) | |
| Riboirino (Germany) | |
| Riboirino 20mg/ml (Germany) | |
| RINOTEC (India) | |
| 40 mg x 2 mL x 1's (United Biotech) | |
| 100 mg x 5 mL x 1's (United Biotech) | |
| Rinotec 40mg x 2mL VIAL / 1 (United Biotech) | |
| Rinotec 100mg x 5nL VIAL / 1 (United Biotech) | |
| RINOTEC 100MG INJECTION 1 vial / 1 injection each (United Biotech) | $ 42.92 |
| RINOTEC inj 40 mg x 2 mL x 2ml (United Biotech) | $ 22.83 |
| RINOTEC inj 100 mg x 5 mL x 5ml (United Biotech) | $ 48.13 |
| Rinotec 40mg x 2mL VIAL / 1 (United Biotech) | |
| Rinotec 100mg x 5nL VIAL / 1 (United Biotech) | |
| Rinotec 100mg Injection (United Biotech) | $ 42.92 |
| Romisan (Indonesia, Netherlands) | |
| Sandoz Irinotecan (South Africa) | |
| Santacil (Greece) | |
| Sibudan (Argentina) | |
| Symtecan (Poland) | |
| Tecnotecan (Brazil) | |
| Tekamen (Turkey) | |
| Tekamen 40 mg/2 mL inj 1's (Musta Nevzat) | |
| Tekazol (Romania) | |
| Terican (Mexico) | |
| Injectable; Injection; Irinotecan Hydrochloride 20 mg / ml (Landsteiner) | |
| Tiagrel (Argentina) | |
| Topotecin (Japan) | |
| TORSIRIN | |
| 40 mg x 2 mL x 1's (Miracalus Pharma Pvt Ltd) | $ 20.48 |
| 100 mg x 5 mL x 1's (Miracalus Pharma Pvt Ltd) | $ 38.55 |
| Torsirin 40mg/2mL VIAL / 1 (Miracalus Pharma Pvt Ltd) | $ 20.48 |
| Torsirin 100mg/5mL VIAL / 1 (Miracalus Pharma Pvt Ltd) | $ 38.55 |
| Torsirin 40 mg Injection (Miracalus Pharma Pvt Ltd) | $ 0.01 |
| Torsirin 100 mg Injection (Miracalus Pharma Pvt Ltd) | $ 0.04 |
| TORSIRIN inj 40 mg x 2 mL x 2ml (Miracalus Pharma Pvt Ltd) | $ 20.48 |
| TORSIRIN inj 100 mg x 5 mL x 5ml (Miracalus Pharma Pvt Ltd) | $ 38.55 |
| Torsirin 40mg/2mL VIAL / 1 (Miracalus Pharma Pvt Ltd) | $ 20.48 |
| Torsirin 100mg/5mL VIAL / 1 (Miracalus Pharma Pvt Ltd) | $ 38.55 |
| Trebyxan (Brazil) | |
| Trinotecan (Argentina) | |
| Viaritec (Serbia) | |
| Vintecan (Greece) | |
| Winol (Argentina) | |
| Xavetta (Netherlands) | |
See 578 substitutes for Satigene | |
References
- PubChem. "irinotecan". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "irinotecan". http://www.drugbank.ca/drugs/DB00762 (accessed September 17, 2018).
- DTP/NCI. "irinotecan: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Satigene are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Satigene. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
